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Abstract
Background: The Middle East respiratory syndrome (MERS) is proposed to be a zoonotic disease. Dromedary camels
have been implicated due to reports that some confirmed cases were exposed to camels. Risk factors for MERS
coronavirus (MERS-CoV) infections in humans are incompletely understood. This study aimed to describe the
demographic characteristics, mortality rate, clinical manifestations and comorbidities with confirmed cases of MERS-CoV.
Methods: Retrospective chart review were performed to identify all laboratory-confirmed cases of MERS-CoV in Saudi
Arabia who reported to the Ministry of Health (MOH) of Saudi Arabia and WHO between April 23, 2014 and August 31,
2015. Patients’ charts were also reviewed for demographic information, mortality, comorbidities, clinical presentations,
health care facility and presented with descriptive and comparative statistics using non parametric binomial test and
Chi-square test.
Results: Confirmed cases of male patients (61.1%) exceeded those of female patients (38.9%). Infections among Saudi
patients (62.6%) exceeded those among non-Saudi patients (37.4%; P = 0.001). The majority of the patients were aged
21–40 years (37.4%) or 41–60 years (35.8%); 43 (22.6%) were aged >61 years, and (8) 4.2% were aged 0–20 years. There
was a difference in mortality between confirmed MERS-CoV cases (63.7% alive versus 36.3% dead cases, respectively).
Furthermore, fever with cough and shortness of breath (SOB) (n = 39; 20.5%), fever with cough (n = 29; 15.3%), fever
(n = 18; 9.5%), and fever with SOB (n = 13; 6.8%), were the most common clinical manifestations associated with
confirmed MERS-CoV cases.
Conclusion: MERS-CoV is considered an epidemic in Saudi Arabia. The results of the present study showed that the
frequency of cases is higher among men than women, in Saudi patients than non-Saudi, and those between 21 to
60 years are most affected. Further studies are required to improve the surveillance associated with MERS-CoV to get
definite and clear answers and better understanding of the MERS-CoV outbreak as well the source, and route of
infection transmission in Saudi Arabia.
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Background
Coronaviruses are large enveloped viruses with a single-
stranded positive-sense RNA genome. They can infect
humans, as well as a variety of animals, such as bats,
mice, birds, dogs, pigs, and cattle, causing mainly re-
spiratory and enteric diseases [1]. The virus MERS-CoV
is a new member of the beta group of coronavirus, Beta
coronavirus. MERS-CoV is different from SARS corona-
virus and different from the common-cold coronavirus and
known as endemic human betacoronaviruses HCoV-OC43
and HCoV-HKU1. MERS-CoV had frequently been re-
ferred to as a SARS-like virus, or the novel coronavirus
until 23 May 2013. On September 11, 2012, a 49-year-old
man from Qatar, with a history of travel to Saudi Arabia,
was transferred to the United Kingdom with symptoms of
severe respiratory illness. Sample from the lower respiratory
tract samples of the patient was found positive after a pan-
coronavirus RT-PCR assay. Comparison of the sequence of
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the PCR fragments with the ones obtained in the case of
the Saudi patient revealed that they share 99% similarity,
suggesting infection by the same virus [1]. Sequencing of
the novel coronavirus was performed at the Erasmus
Medical Center (EMC) in Rotterdam, the Netherlands,
where the virus was named “human coronavirus EMC”
(hCoV-EMC) [2]. Later, the Coronavirus Study Group of
the International Committee on Taxonomy of Viruses
renamed the virus “Middle East respiratory syndrome
coronavirus” (MERS-CoV) in May 2013 [3].
MERS-CoV is a zoonotic virus that is transmitted
from animals that are a reservoir of the virus to humans.
Although the source of MERS-COV is not elucidated
yet, camels are the most likely source of infection in
human [3, 4]. A coronavirus similar to large extent to
the one detected in humans has been isolated from camels
in Egypt, Oman, Qatar, and Saudi Arabia. Other animals
including goats, cows, sheep, water buffalo, swine, and
wild birds, have been tested for MERS-CoV and only
dromedary camels have evidence of sero-positivity to
MERS-COV, supporting the premise that dromedary
camels are a likely source of infection in humans [3].
Direct contact with the saliva of infected camels, or
consumption of contaminated milk or meat was the
suspected transmission route for human MERS-COV
infection [4]. Previous study found that the seropreva-
lence of MERS-CoV was several times higher in persons
with regular exposure to camels than in the general
population [5, 6]. However, there are some cases infec-
tion in which the patients do not have any contact with
sick animals or their products. This might be human to
human route of transmission.
Only limited numbers of zoonotic diseases have been
reported to be transmitted from human to human [7].
The incapability of MERS-CoV to infect animal models
like hamsters, mice, and ferrets, indicates the presence of
a species barrier. However, an experimental study showed
that human cell lines were susceptible to MERS-CoV in-
fection [8], and the reports of human-to-human transmis-
sion have increased [9–11]. The modes of human-to-
human MERS-CoV spread are incompletely defined [12].
Emergence of the Middle East respiratory syndrome
coronavirus (MERS-CoV) has caused significant concern.
A total of 635 laboratory-confirmed cases of MERS-CoV
infection have been reported globally, including 193
deaths. Cases of MERS-CoV in Saudi Arabia were
reported for the first time in September 2012, following
the death of a patient due to a severe respiratory illness
[13–15]. Little is known regarding the extent of human
infection or the degree of detection bias towards more
severe cases. If the severe cases currently being detected
represent only a small sentinel minority of a much larger
population of milder cases (as occurred in the early stage
of the 2009 H1N1 pandemic in Mexico) [16], the case-
fatality ratio might be substantially lower than what
current surveillance data suggest. Conversely, for the se-
vere acute respiratory syndrome (SARS) epidemic of 2003,
there was little evidence of the existence of undetected
mild or subclinical infections [17–20].
Risk factors for the disease in humans are incompletely
understood [21], although MERS is proposed to be a
zoonotic disease. Dromedary camels have been impli-
cated due to reports that some confirmed cases were
exposed to camels. In the Middle East, confirmed cases
of MERS-CoV have arisen as sporadic, familial, or hos-
pital clusters [13, 22–26]. Although human-to-human
transmission of MERS-CoV has been identified in many
European, African, and Middle Eastern countries, [27–30]
a genomic analysis of the Riyadh MERS-CoV isolates
suggested that there were three genetically distinct line-
ages of MERS-CoV; therefore, it was unlikely that the
Riyadh infections were the result of a single, continuous
chain of human-to-human transmission [15, 31, 32]. A
recent study provided further evidence of non-sustainable
transmission among humans and suggested that transmis-
sion within Saudi Arabia was dependent on contact with
an animal reservoir or animal products [14]; however, no
animal reservoir has yet been identified. While contact
with camels has been reported, these reports were limited
to only the primary cases [22, 33–37]. The MERS-CoV
was related with a strain of severe acute respiratory syn-
drome coronavirus (SARS-CoV) that caused an outbreak
in 29 countries in 2002–2003. This outbreak was charac-
terized by 8273 cases and 775 deaths, with the majority of
cases in Hong Kong [16]. As was determined for the
SARS-CoV during its pre-pandemic stage, the MERS-
CoV has likely been repeatedly transmitted from an
unknown animal host to humans in the past year [17–20].
To obtain effective control of the MERS-CoV out-
break, the MOH of the Kingdom of Saudi summoned a
Rapid Response Team (RRT). The RRT was composed
of 15 infectious disease doctors and two infection
control professionals affiliated with the Korean Society
for Infectious Diseases and the Korean Society for
Healthcare-associated Infection Control and Prevention.
The RRT established national infection control and pre-
vention guidelines for the diagnosis and management of
MERS-CoV infections [32, 38–41]. The current study
aimed to investigate the demographic characteristics,
history of contact with camels or positive cases, mortality,




All laboratory confirmed MERS-CoV cases who were
reported by the Saudi Ministry of Health to WHO from
April 23, 2014 to August 31, 2015, were identified.
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Patient’s charts were reviewed for demographic informa-
tion, mortality, comorbidities, clinical presentations and
health care facility.
Case definition
A confirmed case was defined as any person with labora-
tory confirmation of MERS-CoV infection based on posi-
tive real-time polymerase chain reaction (PCR) of MERS-
CoV in swab samples collected by the MOH in addition to
any one of the following clinical definitions: fever (>38 °C),
a cough, shortness of breath (SOB), sore throat, vomiting,
diarrhea, hemoptysis, chest pain and/or infection, respira-
tory failure, loss of consciousness, runny nose and any
asymptomatic outpatients with a history of contact with
positive symptomatic cases and tested positive. Patients
provided their signed consent to publication where legal
guardian provided consent for a minor.
Molecular testing
All PCR testing was carried out at the Saudi Ministry
of Health MERS-CoV regional laboratory in Riyadh.
Respiratory samples were obtained from all patients
and submitted to the regional lab to be tested for
MERS-COV infection using primers that amplify both
the upstream E protein (upE) and ORF1a genes. Samples
that tested positive for both upE and Orf 1a gene targets
were considered confirmed cases. Each patient was tested
at least twice, each on a different day.
Statistical analysis
Differences were assessed for significance using chi-square
goodness of fit and non-parametric binomial tests, where
appropriate. Statistical analyses were performed using
SPSS, version 21 software (IBM Corp., Armonk, NY,
USA). P < 0.05 was considered statistically significant.
Results
As is shown in Table 1, the confirmed male-to-female
case ratio was 1.6:1. There were significantly more infec-
tions among Saudi patients than among non-Saudi
patients (62% versus 37.4%; P = 0 · 001; Table 1). Of the
190 patients, 141 (74.2%) had no history of contact with
camels or positive cases. A total of 147 (73.2%) patients
were aged 20–60 years. The lowest percentage of pa-
tients was younger than 20 years of age. Of the 190
patients with confirmed MERS-CoV infection, 69 patients
(36.3%) died and 121 patients (63.7%) lived (Table 2). The
most common symptoms at presentation were (fever,
cough, SOB) (n = 39; 20.5%), (fever, cough) (n = 29; 15.3%),
fever (n = 18; 9.5%), (fever, SOB) (n = 13; 6.8%), (SOB,
cough) (n = 6; 3.2%), and Respiratory Failure (n = 3; 1.6%)
(Fig. 1). Other symptoms were reported less frequently by
5% of patients including chest infection; cold, cough, SOB;
cough, diarrhea; cough, SOB, hemaptisis; fever, cough,
SOB, vomiting and cough, SOB. All 27 asymptomatic
patients (14.2% of 190) with a history of contact with posi-
tive symptomatic cases were tested positive (Fig. 1).
Figure 2 presents frequency and distribution of the
confirmed cases that were admitted to health facilities
from different provinces in Saudi Arabia. In Riyadh, the
majority of cases were reported from the Eastern region
of Riyadh (113 cases, (59.5%)). 29 cases (15.3%) from
Central region of Riyadh, 15 cases (7.9%) from North
region in Riyadh, 12 cases (6.3%) from South region of
Riyadh and 4 cases (2.1%) from West region in Riyadh.
On the other hand, 16 cases (8.4%) collectively reported
from other provinces in Saudi Arabia. Of the 190
patients, 108 (56.8%) had underlying medical disorders,
and 82 (43.2%) were previously healthy (Table 3).
Diabetes 60 (31.6%), hypertension 54 (28.4%) and bron-
chial asthma 18 (9.5%) were the most frequent comorbid
disorders (Table 3).
Discussion
Of the 190 (116 men and 74 women) confirmed cases of
MERS-CoV infection in our study, only a single patient
Table 1 Demographic characteristics of Middle East respiratory
syndrome coronavirus cases in Saudi Arabia between April 23,
2014 and August 31, 2015












History of contact <0.0001
Camels or 1 (0.5)
positive case 48 (25.3)
None 141 (74.2)
Data are n (%)
Table 2 Mortality rates of confirmed versus suspected cases of
Middle East respiratory syndrome coronavirus between April 23,
2014 and August 31, 2015
Outcome Confirmed P-value
Survival 121 (63.7) <0.0001
Death 69 (36.3)
Total 190
Data are n (%)
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had a history of direct contact with camels and 48 had
direct contact with positive cases of MERS-CoV; 141
patients did not have any contact with camels and other
sick patients. An analysis of the demographic character-
istics of the confirmed cases of MERS-CoV during the
18-month study period demonstrated that only eight
cases were patients aged <20 years; 73.2% of the cases
were patients aged 21–60 years, and 22.6% of the cases
were patients aged >61 years. Notably, a high number
(37.4%) of the confirmed cases of MERS-CoV were not
of Saudi nationality.
The respiratory clinical manifestations of MERS-CoV
infection for all of the patients in the present study were
similar to those observed in previous studies of other
Saudi patients from different regions in Saudi Arabia.
Fever with cough and SOB, then fever with cough were


























Fig. 1 Clinical manifestations of patients with confirmed Middle East
respiratory syndrome coronavirus (n = 190) between April 23, 2014
and August 31, 2015
Fig. 2 Distributions of Middle East respiratory syndrome coronavirus cases in Saudi Arabia between April 23, 2014 and August 31, 2015
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and 15.3%, respectively). These findings are consistent
with previous reports [21, 22, 38, 42–47].
Notably, the clinical features of MERS-CoV infection
ranged from asymptomatic or mild disease to acute
respiratory distress syndrome and multi-organ failure,
which is consistent with the findings of previous studies
from various countries [33, 34, 40, 43, 47, 48]. To date,
only three studies have reported the clinical characteris-
tics and outcomes of patients with MERS-CoV infection
who were admitted to the intensive care unit (ICU),
which collectively included 34 patients [44–47, 49, 50].
Arabi et al. analyzed data for 12 patients admitted to
two ICUs in Riyadh and one in Al-Hasa in the central and
eastern parts of the country, respectively [47]. The
remaining two reports were both from Jeddah in Western
Saudi Arabia. The study by Al-Hameed et al. included
eight patients [44], whereas Khalid et al. described the
clinical course and outcomes of 14 patients with severe
MERS-CoV infection [50].
There is a need to improve the collaboration between
scientific researchers, clinical units, and public health
communities in order to provide an effective community
health service and to prepare for future outbreaks of
MERS-CoV, to ultimately decrease the number of new
cases [22, 29, 35, 47, 48]. The MERS-CoV outbreak in
Saudi Arabia appeared to be reaching controlled levels,
with a significant decrease in the number of new cases.
Furthermore, there were no new super spreading events
that could result in a third epidemic peak. Vigilant
monitoring will be crucial to end the MERS-CoV out-
break. The RRT hopes to share their knowledge of the
MERS-CoV outbreak with other countries and to co-
operate in the prevention of the MERS-CoV outbreak
from becoming a global pandemic.
Conclusion
MERS-CoV is considered an epidemic in Saudi Arabia.
The results of the present study showed that the fre-
quency of cases is higher among men than women, in
Saudi patients than non-Saudi, and those between 21 to
60 years are most affected. Furthermore, Eastern Region
of Riyadh had the highest number of cases. However,
further studies are required to determine association of
demographic characteristics with mortality, source, and
route of infection transmission in Saudi Arabia. We
recommend that much more studied are remains to be
discovered about MERS-CoV. Improved surveillance,
epidemiological research for the development of new
therapies and vaccine are important for both human and
camels. Further studies are required to gains in terms of
better understanding of disease patterns should be main-
tained to enable the global community to answer the
remaining questions about this disease.
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Table 3 Frequency of comorbidities in patients with confirmed
Middle East respiratory syndrome coronavirus
Comorbidities Patients
Diabetes mellitus 60 (31.6)
Hypertension 54 (28.4)
B. asthma 18 (9.5)
IHD 11 (5.8)
CHF 5 (2.6)




Liver cirrhosis 2 (1.1)
HF 1 (0.5)
BPH 1 (0.5)
Hodgkin’s lymphoma 1 (0.5)
Chronic obstructive pulmonary disease 1 (0.5)
Sickle cell anemia 1 (0.5)
Liver carcinoma 1 (0.5)
Mitral + aortic valve replacement 1 (0.5)
Acute respiratory distress syndrome 1 (0.5)
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